Supernus Pharmaceuticals Dividenden en inkoop
Dividend criteriumcontroles 0/6
Supernus Pharmaceuticals heeft geen dividenduitkeringen gedaan.
Belangrijke informatie
n/a
Dividendrendement
-1.2%
Terugkoop Rendement
| Totaal aandeelhoudersrendement | -1.2% |
| Toekomstig dividendrendement | 0% |
| Dividendgroei | n/a |
| Volgende betaaldatum dividend | n/a |
| Ex-dividenddatum | n/a |
| Dividend per aandeel | n/a |
| Uitbetalingsratio | n/a |
Recente updates van dividend en inkoop
Geen updates
Recent updates
SUPN: Resolved Supply Constraints Will Support Future Repricing Potential
Analysts have lifted their price target on Supernus Pharmaceuticals by $5 to $65, citing refreshed models after Q4 results and improved visibility on Onapgo supply as production ramps up with the current supplier and a second source expected in 2027. Analyst Commentary Bullish Takeaways Bullish analysts view the $65 price target, up from $60, as reflecting refreshed forecasts after the latest Q4 update.SUPN: Resolved Supply Constraints And Dual Sourcing Plans Will Support Future Repricing
Narrative Update: Supernus Pharmaceuticals Analyst Price Target Shift Analysts have lifted their price target on Supernus Pharmaceuticals to $65 from $60, citing updated models after Q4 results and expectations that Onapgo supply constraints are now addressed with increased production capacity and a planned second supplier in 2027. Analyst Commentary Analysts see the updated price target as a reflection of fresh Q4 inputs and improved visibility on Onapgo supply.SUPN: Resolved Supply Constraints Will Support Repricing Through Improved Execution
Analysts have lifted their price target on Supernus Pharmaceuticals to $65 from $60, citing updated models after Q4 results and expectations that Onapgo supply constraints are easing with increased production capacity and an additional supplier planned for 2027. Analyst Commentary Bullish Takeaways Bullish analysts see the higher US$65 price target as a reflection of updated models that better align with recent Q4 information and current expectations for the business.SUPN: Supply Resolution And Refined P/E Assumptions Will Support Repricing
Analysts have increased their price target on Supernus Pharmaceuticals to $65 from $60, citing updated models following Q4 results and expectations that Onapgo supply constraints are now resolved with expanded production capacity. Analyst Commentary Bullish Takeaways Bullish analysts see the higher US$65 price target as a reflection of updated Q4 assumptions that support their view of improved execution and earnings potential.SUPN: Stable Fair Value And Refined P/E Assumptions Will Support Repricing
Analysts modestly adjusted their $61.33 price target on Supernus Pharmaceuticals as they updated their assumptions around revenue growth, profit margin, and future P/E. This reflects a more finely tuned view of the company’s earnings power and valuation risk.SUPN: Steady Fair Value And P/E Outlook Will Support Bullish Repricing
Analysts have kept their price target for Supernus Pharmaceuticals broadly steady, citing only modest tweaks to underlying assumptions such as a slightly higher discount rate, minor adjustments to expected revenue growth and profit margin, and a largely unchanged future P/E outlook. Valuation Changes Fair Value Estimate remains unchanged at 61.33.Supernus: Outlook For 2026 Positive, Upholding Buy Rating
Feb 01SUPN: Higher 2025 Revenue Guidance Will Support Expanded Future Earnings Multiple
Analysts have adjusted their price target on Supernus Pharmaceuticals to US$61.33 per share, reflecting updated assumptions around discount rate, revenue growth, profit margin, and future P/E that remain broadly in line with prior estimates. What's in the News Supernus Pharmaceuticals raised its 2025 total revenue guidance to a range of US$685 million to US$705 million, including approximately US$75 million to US$85 million from Trokendi XR and Oxtellar XR (Key Developments).SUPN: Higher 2025 Revenue Guidance Will Support Expanded Future Earnings Multiple
Analysts have inched their price target on Supernus Pharmaceuticals higher by about $0.83, citing updated assumptions that include a modest adjustment to fair value, slightly different revenue growth and profit margin expectations, and a higher future P/E multiple. What's in the News Supernus Pharmaceuticals raised its 2025 total revenue guidance to a range of US$685 million to US$705 million, including approximately US$75 million to US$85 million from Trokendi XR and Oxtellar XR (Key Developments).SUPN: Faster Therapy Adoption Will Drive Shares Toward Higher Future Upside
Analysts have raised their price target on Supernus Pharmaceuticals to $65, up from $40, citing a faster than expected ramp for ONAPGO and the potential for additional upside beyond current peak sales assumptions. Analyst Commentary Recent research updates reflect a constructive shift in sentiment toward Supernus, with multiple firms lifting price targets and emphasizing the upside from ONAPGO's adoption curve.SUPN: Upgrades Will Drive Future Upside As Revenue Outlook Tightens
Analysts have raised their price target on Supernus Pharmaceuticals to $65 from $40, reflecting growing confidence in stronger ONAPGO uptake and expanded long term earnings potential. Analyst Commentary Recent Street research reflects a more constructive stance on Supernus, with higher price targets supported by improving ONAPGO assumptions and a clearer long term earnings trajectory.SUPN: Upgrades Will Drive Momentum As Earnings Guidance Increases
Analysts have raised their price target for Supernus Pharmaceuticals from $59.33 to $60.50, citing improved revenue growth expectations and increased peak sales forecasts for ONAPGO. Analyst Commentary Recent Street research reflects growing optimism around Supernus Pharmaceuticals, as analysts adjust their targets and ratings in response to strong expectations for ONAPGO and the company’s broader growth trajectory.SUPN: Upgrades And Revenue Outlook Will Shape Performance Amid Execution Risk
Analysts have raised their price target for Supernus Pharmaceuticals by over $4 to approximately $59.33 per share. This change is due to higher future revenue growth expectations and an improved outlook for key therapies.Analysts Boost Price Targets for Supernus Pharmaceuticals on Accelerating Growth and Revenue Outlook
Supernus Pharmaceuticals’ analyst price targets have risen sharply, with the fair value estimate increasing from $49.20 to $55.20 per share as analysts cite accelerating growth prospects and higher peak sales potential in key product lines. Analyst Commentary Bullish Takeaways Bullish analysts have raised their price targets substantially, with figures as high as $65 per share.Widening CNS Access Will Shape Long-term Market Opportunity
Analysts have raised their fair value estimate for Supernus Pharmaceuticals from $40.20 to $49.20, citing a stronger forecast for blockbuster products and higher projected profit margins. This has resulted in a more than $9 increase in their price target.We Ran A Stock Scan For Earnings Growth And Supernus Pharmaceuticals (NASDAQ:SUPN) Passed With Ease
Sep 10
Benign Growth For Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Underpins Its Share Price
Jul 23Shareholders Can Be Confident That Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings Are High Quality
May 13Investor Optimism Abounds Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) But Growth Is Lacking
Feb 10Supernus: New Approval Holds Promise Of Increased Growth
Feb 06Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth
Nov 12Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Share Price Could Signal Some Risk
Oct 31
Qelbree And GOCOVRI Spearhead Robust Revenue Surge, Setting The Path For Market Domination In CNS Therapeutics
Supernus Pharmaceuticals shows robust growth potential with advancements in its product pipeline and significant net sales growth from key products like Qelbree and GOCOVRI.Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives
Sep 12Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings
Aug 19Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout
Jul 02Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price
Apr 24Supernus Pharmaceuticals: Moving Through An 'Inflection Year'
Mar 04We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt
May 10Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?
Feb 03Stabiliteit en groei van betalingen
Dividenden ophalen
Stabiel dividend: Er zijn onvoldoende gegevens om te bepalen of het dividend per aandeel van SUPN in het verleden stabiel is geweest.
Groeiend dividend: Er zijn onvoldoende gegevens om te bepalen of de dividendbetalingen van SUPN zijn gestegen.
Dividendrendement versus markt
| Supernus Pharmaceuticals Dividendrendement versus markt |
|---|
| Segment | Dividendrendement |
|---|---|
| Bedrijf (SUPN) | n/a |
| Markt onderkant 25% (US) | 1.4% |
| Markt Top 25% (US) | 4.2% |
| Gemiddelde industrie (Pharmaceuticals) | 2.2% |
| Analist prognose (SUPN) (tot 3 jaar) | 0% |
Opmerkelijk dividend: Het dividendrendement van SUPN kan niet worden vergeleken met dat van de onderste 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.
Hoog dividend: Het dividendrendement van SUPN kan niet worden vergeleken met dat van de top 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.
Winstuitkering aan aandeelhouders
Verdiendekking: Er zijn onvoldoende gegevens om de payout ratio SUPN te berekenen en vast te stellen of de dividendbetalingen worden gedekt door de winst.
Contante uitbetaling aan aandeelhouders
Kasstroomdekking: De duurzaamheid van het dividend kan niet worden berekend, omdat SUPN geen uitbetalingen heeft gerapporteerd.
Ontdek bedrijven met een sterk dividend
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/04 14:55 |
| Aandelenkoers aan het einde van de dag | 2026/05/01 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Supernus Pharmaceuticals, Inc. wordt gevolgd door 17 analisten. 6 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Emily Bodnar | Berenberg |
| Chi Meng Fong | BofA Global Research |
| Pavan Patel | BofA Global Research |